chunyang zhou

Dr. chunyang zhou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
WGWen Guo
Wen Guo
RHRong Huang
Rong Huang
JBJiaojiao Bian
Jiaojiao Bian
QLQing Liao
Qing Liao
JYJun You
Jun You
ZXZhengmin Xu
Zhengmin Xu

1 January 2021 in Open Medicine
Verified
Journal Article
Open access
PDF file
XOXuelan Ou
Xuelan Ou
TXTianqin Xia
Tianqin Xia
CYChunyan Yang
Chunyan Yang
CYChunlei Yu
Chunlei Yu
SZShipeng Zhang
Shipeng Zhang
CZchunyang zhou
chunyang zhou
As a gaseous mediator, hydrogen sulfide (H2S) has many physiological effects and pathological effects in atherosclerosis. In recent years, many exogenous H2S donors have been synthesized to study atherosclerosis diseases. In this study, proglumide-(5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione) (P-A) was synthesized as a H2S donor. The protective effect and mechanism of P-A on HUVEC that was injured by ox-LDL were detected. The HUEVCs were affected by 100 μmol/L P-A for 24 h; the release of H2S was the largest. After 100 μmol/L P-A acted on HUVEC damage model for 12 h, the cell proliferation activity was the best. The results showed that P-A can downregulate the expression of p-NF-кBp65 protein and reduce the amount of TNF-α and IL-6 and promote the formation of IL-10 by inhibiting the NF-кB pathway, and also induce the expression of superoxide dismutase (SOD) to protect HUVEC from ox-LDL injury. P-A can also regulate JAK/STAT pathway to reduce the expression of p-JAK2 protein and reduce the production of IL-6 and TNF-α. P-A has protective effect on HUVEC injured by ox-LDL, and the protective mechanism is related to the regulation of JAK/STAT pathway and NF-кB pathway.

8 September 2025 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
YTYue Tang
Yue Tang
YTYue Tian
Yue Tian
YWYi Wang
Yi Wang
XMXue Mei
Xue Mei
LLLijun Luo
Lijun Luo
CZchunyang zhou
chunyang zhou
Introduction: Atherosclerosis (AS) is a primary cause of cardiovascular disease and significantly contributes to the global disease burden. Empagliflozin (EMP), a candidate drug for AS treatment, has not been clinically approved due to challenges including poor solubility, low bioavailability, and potential toxicity.Methods: To address these challenges, we constructed a platelet membrane-biomimetic, mitochondria-targeted delivery system (PM@EPPT). This system was developed by loading EMP into PCL-PEG polymeric micelle, modifying the PEG terminus with triphenylphosphine (TPP), and coating the nanoparticle surface with platelet membranes. We then evaluated its efficacy against AS using both in vitro and in vivo models.Results: The PM@EPPT system exhibited favorable physical properties and biocompatibility. In vitro, it alleviated oxidative stress-induced macrophage apoptosis by scavenging reactive oxygen species (ROS), restoring mitochondrial membrane potential, and activating mitophagy. In ApoE-/- mouse models, PM@EPPT significantly reduced aortic plaque area by 43%, decreased the expression of inflammatory markers (CD68 and MMP-9), increased levels of the plaque stability marker (α-SMA), and improved lipid profiles.Discussion: In conclusion, PM@EPPT enhances EMP bioavailability through platelet membrane-mediated arterial plaque targeting and TPP-modified mitochondrial targeting. This study provides experimental evidence for optimizing EMP efficacy in AS treatment and developing therapeutic platforms for other poorly soluble drugs targeting AS.

27 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YWYihua Wang
Yihua Wang
QLQing Liao
Qing Liao
XMXue Mei
Xue Mei
HXHan Xu
Han Xu
LLLijun Luo
Lijun Luo
CZchunyang zhou
chunyang zhou
Atherosclerosis (AS) is a major global contributor to cardiovascular diseases and associated mortality. The traditional treatment primarily relies on statins; however, these drugs are often linked to side effects such as liver dysfunction and muscle impairment. Recent studies have highlighted the potential protective properties of saponin compounds derived from traditional herbal sources, such as notoginsenoside R1 (NGR1) and saikosaponin B2 (SSB2), in combating atherosclerosis. However, the comprehensive effects of these compounds against atherosclerosis and their underlying mechanisms remain inadequately understood. Firstly, we employed network pharmacology analysis to identify 113 common targets, including mTOR and CASP3, for NGR1, SSB2, and atherosclerosis from databases such as TCMSP. We constructed a protein-protein interaction (PPI) network and performed GO and KEGG enrichment analyses, whcih revealed key signaling pathways involved in PI3K/Akt, inflammation, and autophagy. The atherosclerosis model was established using ApoE-/- mice fed with a “Western diet” followed by treatment with NGR1, SSB2, or NS combination. Histological examinations, including hematoxylin-eosin (HE) staining, oil red O (ORO) staining, and CD68 immunofluorescence, were conducted to evaluate the pathological conditions of the aortic root, liver and kidneys in ApoE-/- mice. Our findings demonstrate that the NS combination improves lipid levels, lipid transport, and unstable plaque formation in ApoE-/- mice without adverse effects on liver or kidney function. Finally, oxidized low-density lipoprotein (ox-LDL) was used to culture RAW264.7 macrophages to establish an in vitro foam cell model. The effects of NS combination on lipid uptake, inflammatory response, apoptosis, the PI3K/Akt/mTOR signaling pathway, and autophagy were evaluated using methods such as CCK-8 assay, Oil Red O staining, immunofluorescence analysis, flow cytometry, RT-PCR, and Western blot analysis. The results indicated that NS combination promoted autophagy by inhibiting the PI3K/Akt/mTOR pathway. This significantly alleviated inflammation, reduced apoptosis, and decreasing lipid accumulation, thereby improving the pathological progression of atherosclerosis. Collectively, this study demonstrates, for the first time, that the NS combination synergistically activates macrophage autophagy by suppressing the PI3K/AKT/mTOR pathway, thereby attenuating lipid accumulation, inflammation, and apoptosis in atherosclerotic models.

1 January 2025 in Open Life Sciences
Verified
Journal Article
Open access
PDF file
RHRong Huang
Rong Huang
XYXi Yong
Xi Yong
TLTingting Li
Tingting Li
HWHuling Wen
Huling Wen
XZXing Zhou
Xing Zhou
CZchunyang zhou
chunyang zhou
15-Lipoxygenase-2 (15-Lox-2) is one of the key enzymes in arachidonic acid (AA) metabolic pathway, which belongs to the unsaturated fatty acid metabolic pathway. This pathway is involved in the foam cell transformation of macrophages during the progression of atherosclerosis (AS). The role of salidroside (SAL) in cardiovascular diseases has been extensively studied, but its impact on macrophage foam cell formation has not yet been clearly clarified. We aimed to determine the effects of 15-Lox-2 deficiency on macrophage (Ana-1 cell) foam cell formation, and those of SAL on 15-Lox-2 -deficient macrophages. 15-Lox-2 -deficient macrophages were generated using short hairpin RNA. Results indicated that 15-Lox-2 expression in the aorta of atherosclerotic patients is lower than that of the normal group. Additionally, 15-Lox-2 deficiency dramatically promoted macrophage uptake of oxidized low-density lipoprotein (ox-LDL) and increased the Cyclin D1 level while dramatically decreasing caspase3 expression. Furthermore, inflammation, complement, and TNF-α signaling pathways, along with IL1α, IL1β, IL18, and Cx3cl1, were activated in 15-Lox-2 -deficient macrophages. These changes were alleviated by SAL through inhibiting AA effects, and the effects of AA on macrophages could be inhibited by SAL. Consistently, phospholipase A2-inhibitor arachidonyl trifluoromethyl ketone (AACOCF3) restored these changes. In summary, SAL reversed the effects of 15-Lox-2 deficiency on macrophages by inhibiting excessive AA and may be a promising therapeutic potential in treating atherosclerosis resulting from 15-Lox-2 deficiency.

23 September 2024 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
KSKaiyue Sun
Kaiyue Sun
SLShudi Luo
Shudi Luo
YJYujia Jiang
Yujia Jiang
JGJiazheng Guo
Jiazheng Guo
XWXi Wang
Xi Wang
CZchunyang zhou
chunyang zhou